Lifestyle intervention in non-alcoholic fatty liver disease in Chengyang District, Qingdao, China

Table 2 Change in physical and biochemical parameters after 6 mo of intervention

Variable	Group	Baseline	6 mo	P value
Gender (M/F)	LS	442/253	442/253	1.457
	CON	221/119	221/119
Age (yr)	LS	39.9 ± 13.1	38.7 ± 12.4	1.658
	CON	37.4 ± 18.2	39.7 ± 14.6
Weight (kg)	LS	88.5 ± 18.4	83.5 ± 21.6	0.036
	CON	84.3 ± 21.8	85.7 ± 16.8
BMI	LS	37.7 ± 12.7	28.2 ± 11.5	0.043
	CON	38.4 ± 17.1	39.7 ± 17.3
Waist circumference	LS	106.3 ± 23.2	99.4 ± 33.7	0.031
(cm)	CON	108.8 ± 15.7	109.3 ± 21.8
ALT (IU/L)	LS	59.3 ± 20.1	49.1 ± 18.3	0.003
	CON	58.3 ± 18.8	59.3 ± 24.5
AST(IU/L)	LS	57.8 ± 26.6	54.2 ± 25.3	0.614
	CON	59.3 ± 12.9	58.6 ± 14.5
GGT (IU/L)	LS	67.8 ± 19.6	61.8 ± 15.2	0.071
	CON	68.3 ± 11.2	69.3 ± 14.1
Cholesterol	LS	5.7 ± 0.9	4.8 ± 1.4	0.046
(mmol/L)	CON	5.8 ± 1.1	5.8 ± 1.8
Triglycerides	LS	2.4 ± 0.4	2.7 ± 0.7	0.785
(mmol/L)	CON	2.2 ± 0.6	2.5 ± 0.5
Fasting glucose	LS	7.5 ± 1.3	6.2 ± 1.6	0.736
(mmol/L)	CON	7.4 ± 1.6	7.1 ± 2.3
Fasting insulin	LS	16.7 ± 4.3	13.4 ± 5.1	0.347
(μIU/mL)	CON	17.5 ± 8.7	18.3 ± 5.6
HOMA-IR	LS	2.4 ± 0.7	1.17 ± 0.6	0.232
	CON	2.3 ± 0.9	2.74 ± 0.7
L/S ratio	LS	0.8 ± 0.3	0.9 ± 0.2	0.894
	CON	0.7 ± 0.2	0.8 ± 0.3
VFA, cm2	LS	145.6 ± 38.7	132.0 ± 59.5	0.137
	CON	148.9 ± 39.4	149.2 ± 41.6
Metabolic syndrome	LS	371 (53.4)	142 (20.4)	0.026
(%)	CON	182 (53.2)	159 (46.8)

BMI: Body mass index; ALT: Alanine transaminase; AST: Aspartate transaminase; GGT: γ-glutamyltransferase; HOMA-IR: Homeostasis model assessment of insulin resistance; VFA: Visceral fat area; L/S: Liver-spleen; CON: Control group; LS: Lifestyle intervention group.